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Abstract
Inflammasomes are cytosolic protein complexes, which orchestrate
the maturation of active IL-1b by proteolytic cleavage via caspase-
1. Although many principles of inflammasome activation have been
described, mechanisms that limit inflammasome-dependent
immune responses remain poorly defined. Here, we show that the
thiol-specific peroxidase peroxiredoxin-4 (Prdx4) directly regulates
IL-1b generation by interfering with caspase-1 activity. We demon-
strate that caspase-1 and Prdx4 form a redox-sensitive regulatory
complex via caspase-1 cysteine 397 that leads to caspase-1 seques-
tration and inactivation. Mice lacking Prdx4 show an increased
susceptibility to LPS-induced septic shock. This effect was pheno-
copied in mice carrying a conditional deletion of Prdx4 in the
myeloid lineage (Prdx4-DLysMCre). Strikingly, we demonstrate that
Prdx4 co-localizes with inflammasome components in extracellular
vesicles (EVs) from inflammasome-activated macrophages. Purified
EVs are able to transmit a robust IL-1b-dependent inflammatory
response in vitro and also in recipient mice in vivo. Loss of Prdx4
boosts the pro-inflammatory potential of EVs. These findings iden-
tify Prdx4 as a critical regulator of inflammasome activity and
provide new insights into remote cell-to-cell communication func-
tion of inflammasomes via macrophage-derived EVs.
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Introduction
Inflammation is the physiologic response to infection or injury and
aims to restore cellular and tissue integrity. Multimeric protein
complexes termed “inflammasomes” are key mediators of acute and
chronic inflammatory responses. They assemble in response to
cellular stress and regulate the maturation and secretion of IL-1-like
cytokines, which induce a potent pro-inflammatory host response
(Schroder & Tschopp, 2010). Pathologic conditions that lead to loss
of control of IL-1b processing and secretion are associated with vari-
ous inflammatory diseases including hereditary periodic fever
syndromes, gout, atherosclerosis (Ridker et al, 2017), and type 2
diabetes (Neven et al, 2004; Martinon & Tschopp, 2005; Dinarello
et al, 2010; Duewell et al, 2010). The NLRP3 (NOD-like receptor
pyrin domain containing 3) inflammasome is the prototypical and
best-studied inflammasome and is strongly expressed in myeloid
cells (Manji et al, 2002). The sensor and scaffolding protein NLRP3
and pro-IL-1b are induced in the presence of LPS (lipopolysaccha-
ride), other TLR or NLR agonists, or certain cytokines such as TNF-
a or IL-1b (Bauernfeind et al, 2009; Franchi et al, 2009). Following
this priming step, NLRP3 is activated by a drop in intracellular K+
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concentrations (Munoz-Planillo et al, 2013) or by reactive oxygen
species (Gaidt et al, 2016; Gross et al, 2016) commonly caused by
various endogenous and exogenous danger signals like extracellular
ATP-induced purinergic receptor P2X7 (P2X7R) activation (Ferrari
et al, 1997), monosodium urate, bacterial-derived pore-forming
toxins, or nigericin (Kanneganti et al, 2006; Mariathasan et al,
2006). Upon activation, NLRP3 oligomerizes and forms a molecular
platform by recruiting the adapter protein ASC (apoptosis-associated
speck-like protein containing a CARD) and pro-caspase-1 (Martinon
et al, 2009). Clustering of pro-caspase-1 molecules leads to proxim-
ity-induced auto-proteolysis into p20 and p10 subunits, which in
turn cleave pro-IL-1b to generate active IL-1b (Dinarello, 1998).
Mature IL-1b is released into the extracellular space alongside active
caspase-1 and oligomeric particles of the NLRP3 inflammasome
(Baroja-Mazo et al, 2014). Ever since an alternative secretory path-
way for the leaderless IL-1b has been reported (Rubartelli et al,
1990), the exact manner of release remains matter of debate.
Suggested mechanisms include exocytosis via secretory lysosomes
(Andrei et al, 1999, 2004), secretion by microvesicle shedding
(MacKenzie et al, 2001), release of multivesicular bodies that may
contain exosomes (Qu et al, 2007), an autophagy-based secretory
pathway (Dupont et al, 2011), gasdermin D-dependent secretion via
pores (Evavold et al, 2018) and a loss of membrane integrity leading
to passive IL-1b release that occurs in parallel with pyroptotic death
of the secreting cell (Shirasaki et al, 2014; Martin-Sanchez et al,
2016).
We have previously shown that the 2-Cys oxidoreductase perox-
iredoxin-4 (Prdx4) is induced in response to microbial danger
signals, particularly downstream of the innate immune receptor
NOD2 and that Prdx4 negatively regulates NF-jB signaling
(Weichart et al, 2006). Here, we report that Prdx4 limits inflamma-
some activity by thiol-mediated inactivation of caspase-1. Mechanis-
tically, we provide evidence that Prdx4 and caspase-1 interact in the
cytosol and form a redox-sensitive regulatory complex via caspase-1
cysteine 397 and a high-molecular-weight (HMW) complex of
Prdx4. Furthermore, we show that Prdx4 is co-localized with
components of the inflammasome in extracellular vesicles (EVs).
Within EVs, loss of Prdx4 resulted in increased levels of cleaved
caspase-1 and IL-1b maturation. Importantly, EVs, derived from
inflammasome-activated macrophages, were able to transmit an IL-
1b-dependent immune response to recipient cells, whereby Prdx4
deficiency boosted the pro-inflammatory potential of EVs. We thus
define a critical role for Prdx4 in the post-translational and post-
secretional regulation of inflammasome activation and induction of
inflammatory responses.
Results
Prdx4 protects from LPS-induced septic shock
To determine how Prdx4 influences inflammatory responses in vivo,
we generated Prdx4-knockout (KO) mice (Appendix Fig S1). Mice
were fertile and showed no spontaneous phenotype. To investigate
the role of Prdx4 during inflammation, we challenged mice with
sub-lethal doses of LPS. We found that Prdx4-deficient mice had
increased body weight loss and delayed restoration of weight
compared to their wild-type (WT) littermates (Fig 1A). Consistent
with the increased body weight loss, Prdx4 KO mice had significant
higher Cxcl1, TNF-a and IL-1b levels in serum and peritoneal
lavages at 24 h post-LPS injection (Fig 1B–D). As IL-1b is a major
mediator of LPS-induced systemic immune responses, we next
blocked IL-1b-mediated signaling using the interleukin-1-receptor
antagonist (IL-1RA) Anakinra. In all IL-1RA-treated animals, weight
loss was attenuated in response to LPS administration and no dif-
ferences were found between Prdx4 KO and WT littermates
(Fig 2A). Also, excessive serum Cxcl1, TNF-a, and IL-1b levels in
LPS-treated Prdx4 KO mice were significantly lowered upon the
injection of IL-1RA (Fig 2B). Thus, we concluded that loss of Prdx4
results in an aggravated inflammatory response, which involves
increased IL-1b signaling.
Prdx4-deficient macrophages display elevated cytokine
responses and inflammasome activation
We next sought to determine the major cellular source of the
increased IL-1b generation. As myeloid cells have been described
as critical producers of pro-inflammatory cytokines in LPS-induced
septic responses (Dinarello et al, 1974; Baracos et al, 1983), we
crossed floxed Prdx4 mice to a LysMCre deleter strain in order to
obtain mice that specifically lack Prdx4 in cells of myeloid origin,
hereafter referred to as Prdx4-DLysMCre (Appendix Fig S2A).
Knockout of Prdx4 was confirmed by Western blot analysis of
bone marrow-derived macrophages (BMDMs) with antibodies
against Prdx4 (Appendix Fig S2B). Since the results from the
whole-body knockout mice showed the largest difference in body
weight loss between 40 and 60 h after LPS injection, Prdx4-
DLysMCre and floxed littermates were monitored for 48 h post-
LPS injection. Comparable to Prdx4 KO mice, Prdx4-DLysMCre
mice showed a significantly increased body weight loss starting
from 36 h after LPS injection until the end point (Fig 2C). Also,
we found higher Cxcl1, TNF-a, and IL-1b levels in the serum of
Prdx4-DLysMCre mice compared to floxed littermates (Fig 2D).
Collectively, these results suggest a critical role of the myeloid
compartment for the Prdx4-mediated protection during endotoxin
shock.
Because Prdx4 deficiency led to increased cytokine responses
following LPS challenge in vivo, we used BMDMs from Prdx4 WT
and KO mice to characterize the altered responses to LPS in more
detail. In a time course of LPS stimulation, we confirmed that LPS-
induced release of Cxcl1 and TNF-a was significantly increased in
Prdx4-deficient BMDMs (Fig 3A). Importantly, we found that the
absence of Prdx4 also led to a time-dependent release of IL-1b. This
is of interest since LPS stimulation alone is usually not sufficient to
trigger significant IL-1b release in WT BMDMs (Hagar et al, 2013;
Kayagaki et al, 2013). Thus, we next induced IL-1b release by acti-
vation of the inflammasome. We confirmed that loss of Prdx4 leads
to excessive release of IL-1b in BMDMs that were primed with LPS
to induce expression of inflammasome components (Bauernfeind
et al, 2009) followed by a time course of ATP treatment (Fig 3B).
Accordingly, we detected increased levels of mature IL-1b in the
supernatant of Prdx4-deficient BMDMs (Fig 3C). Next, we used
HEK293 cells that were forced to secrete IL-1b by pro-IL-1b/caspase-
1 overexpression. In line with our previous findings, co-expression
of Prdx4 decreased levels of mature IL-1b (Appendix Fig S3). Since
previous reports demonstrated a role for Prdx4 in the redox-
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dependent regulation of NF-jB activation (Jin et al, 1997; Weichart
et al, 2006; Yu et al, 2010) and reactive oxygen species (ROS) also
contribute to NF-jB-dependent NLRP3 priming (Bauernfeind et al,
2011), we hypothesized that Prdx4 deficiency might affect
inflammasome priming leading to the observed differences in IL-1b
levels. Unexpectedly, we did neither find genotype-dependent dif-
ferences on Nlrp3 protein levels or stability, nor on Nlrp3 or Il1b
mRNA levels in response to LPS-induced priming or on other
inflammasome components or redox proteins related to inflamma-
some activation (Fig EV1). To investigate whether the formation of
ASC specks downstream of inflammasome activation is affected by
Prdx4, BMDMs were stimulated with nigericin after LPS priming or
left untreated. We did not find differences in ASC speck formation
(Fig 3D), indicating that increased IL-1b levels in Prdx4 KO BMDMs
do not result from increased ASC speck formation. However, we
detected increased levels of cleaved caspase-1 in the supernatant of
Prdx4 KO BMDMs after nigericin-induced inflammasome activation
(Fig 3E), indicating that Prdx4 negatively influences caspase-1 acti-
vation. In order to validate whether unrestrained caspase-1 activity
accounts for the IL-1b hypersecretion in Prdx4-deficient BMDMs, we
used the selective caspase-1 inhibitor YVAD. We found that YVAD
completely reduced the elevated IL-1b levels in the supernatant of
Prdx4-deficient BMDMs (Appendix Fig S4), confirming that Prdx4-
dependent IL-1b hypersecretion is dependent on caspase-1. Next,
we investigated the impact of Prdx4 on canonical caspase-1
inflammasome activation and IL-1b release. We found that loss of
Prdx4 led to increased IL-1b release compared to WT BMDMs in
response to canonical inflammasome activation induced by either
ATP and nigericin (NLRP3 inflammasome), double-stranded DNA
(AIM2 inflammasome), or flagellin (NLRC4 inflammasome),
although the highest fold change was found for ATP and nigericin
stimulation (Fig 3F). Interestingly, the ATP-, nigericin-, and
flagellin-induced LDH release was affected by Prdx4 as well
(Fig 3G). We therefore concluded that Prdx4 negatively regulates
caspase-1-dependent inflammasome responses in myeloid cells.
Prdx4 interacts with C397 of caspase-1 to block its function
In order to investigate the molecular mechanism by which Prdx4
negatively regulates caspase-1-dependent inflammasome activation,
we hypothesized that Prdx4 directly interacts with caspase-1 to limit
its downstream cleavage and activation. To test this hypothesis, we
assessed whether Prdx4 and caspase-1 interact in vitro using active
forms of recombinant human PRDX4 (rPRDX4) and human caspase-
1 (rCASP-1). Under physiologic conditions and depending on the
redox environment, Prdx4 is known to form oligomeric high-mole-
cular-weight (≥ 250-kDa) structures, with a high abundance of deca-
mers consisting of five disulfide-linked dimers (Tavender et al,
2008). We therefore co-incubated rPRDX4 with rCASP-1 and
analyzed the proteins under non-reducing conditions, in order to
preserve disulfide bridges and to detect the presence of disulfide-
linked complexes. Notably, we detected rCASP-1 at approx.
250 kDa, corresponding to the size of the described PRDX4 decamer
with a concurrent reduction of rCASP-1 p10 levels (Fig 4A). This
suggested a direct interaction of rCASP-1 with the PRDX4 high-mole-
cular-weight complex (HMWC). In order to verify this finding by an
independent approach, we performed HPLC-MS analysis from cut-
out bands of Coomassie-stained SDS–PAGE under non-reducing
conditions. Within the gel bands corresponding to the size of the
Prdx4 decamer/HMWC, we detected peptides corresponding to the
p10 as well as to the p20 subunit of rCASP-1 (Fig EV2, Table EV1).
Additionally, we observed that co-incubation of rCASP-1 with
rPRDX4 resulted in a decrease of the Prdx4 band intensity at approx.
250 kDa and the appearance of an additional band at approx.
50 kDa (longer exposure of WB), which corresponds to the molecu-
lar weight of a Prdx4 dimer. To rule out that caspase-1 catalytically
cleaves Prdx4, we searched for putative caspase-1 cleavage sites in
the mature Prdx4 protein using MEROPS (Rawlings et al, 2018)
(www.ebi.ac.uk/merops/) and ExPaSy (Artimo et al, 2012) (www.e
xpasy.org/) databases, which did not result in predicted target
motifs. Moreover, overexpression of the catalytically inactive p20
C285S active-site mutant did not terminate the shift of p20 into the
Prdx4 decamer/HMWC, nor the occurrence of the weaker band
corresponding to the molecular weight of the Prdx4 dimers
(Appendix Fig S5A), arguing against a caspase-1-mediated cleavage
of Prdx4. We therefore hypothesized that Prdx4 controls caspase-1
function in a thiol-specific manner resulting in the integration of
caspase-1 into the Prdx4 decamer leading to its inactivation. Thus,
we next tested whether the integration of caspase-1 by Prdx4 deca-
mers depends on cysteine residues of caspase-1. We alkylated rCas-
pase-1 (CA), rPrdx4 (PA), or both proteins (CA+PA) with
iodoacetamide before their co-incubation, thereby disabling the
formation of intermolecular disulfide bonds. Under all conditions
tested, alkylation terminated the integration of rCASP-1 into the
rPRDX4 decamer/HMWC (Fig 4B), implying that caspase-1 and
Prdx4 interact via disulfide bridges. We then determined whether
caspase-1 function is specifically altered by non-reduced Prdx4
complexes and measured caspase-1 activity in the presence of non-
reduced or the reduced form of Prdx4. Indeed, we found that non-
reduced rPRDX4 significantly inhibited caspase-1 activity whereas
the reduced form of rPRDX4 had no significant effect (Fig 4C). In
order to control for specificity, we co-incubated rPRDX4 with
rGAPDH, which contains an active-site cysteine, known to be redox-
sensitive (Nakajima et al, 2009). However, co-incubation with non-
reduced rPRDX4 had no impact on the oligomeric structure of the
homotetrameric rGAPDH (Appendix Fig S5B), pointing toward a
◀ Figure 1. Prdx4 protects from LPS-induced septic shock.A Percent body weight of male Prdx4 WT and KO mice over the 72 h course of LPS (4.5 mg/kg BW) or PBS injection (i.p.). Each circle represents a mean of n = 7 mice;
vertical lines indicate SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (two-way-ANOVA, Bonferroni post-test).
B–D Cytokine concentration in Prdx4 WT and KO mice in response to LPS injection. (B) Cxcl1 levels in serum (left) or peritoneal lavage (right) at indicated time points
after LPS or PBS injection. (C) TNF-a levels in serum (left) or peritoneal lavage (right) at indicated time points after LPS or PBS injection. (D) IL-1b levels in serum
(left) or peritoneal lavage (right) at indicated time points after LPS or PBS injection. Each dot represents an individual mouse. Horizontal lines indicate mean.
**P < 0.01; ***P < 0.001; n.s. not significant (two-tailed t-test). Data are representative of two independent experiments.
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specific disulfide bond exchange between caspase-1 and Prdx4.
Together, this confirmed that (i) caspase-1 and Prdx4 interact in a
disulfide-dependent manner and (ii) a high-molecular-weight
complex of Prdx4 controls caspase-1 activity.
Next, we wanted to know whether this can be attributed to a
specific cysteine residue of caspase-1. The cysteines C362 and C397
have previously been found to be modified by glutathione and their
mutation into serine resulted in increased caspase-1 activity (Meiss-
ner et al, 2008). We thus hypothesized that the Prdx4-mediated
decrease of caspase-1 activity would be lost in a Cys-to-Ser mutant
that displays sensitivity toward Prdx4. We therefore overexpressed
the gain-of-function Cys-to-Ser mutants C362S, C397S, or the C285S
active-site mutant together with either Prdx4 or a control and
analyzed subsequent IL-1b secretion. We confirmed that C362S and
C397S mutants exhibited increased caspase-1 activity compared to
WT caspase-1 when Prdx4 was not co-expressed (Fig 4D), whereas
the C285S active-site mutant, as expected, showed no effect. In the
presence of Prdx4, caspase-1 C362S activity was decreased
compared to the control, whereas it remained unaltered in the
C397S mutant. This indicated that the cysteine 397 of caspase-1 is
responsive to Prdx4 and mediates the Prdx4-induced caspase-1 inhi-
bition. To underscore this finding, we analyzed the interaction of
caspase-1 with the high-molecular-weight form of Prdx4 under non-
reducing conditions. To this end, cells were transfected with
caspase-1 WT, C362S, C397S, or C362S plus C397S mutants in the
presence or absence of co-transfected Prdx4. We found that overex-
pression of the C397S as well as the C362S plus C397S mutants
strongly decreased the formation of the Prdx4-caspase-1 high-mole-
cular-weight complex (Fig 4E), indicating that the C397 of caspase-1
forms the disulfide bridge with Prdx4. To confirm this result, we
performed co-immunoprecipitation from cells that were transfected
with caspase-1 WT, C362S, C397S, or C362S plus C397S mutants in
the presence or absence of co-transfected Prdx4. Notably, Prdx4 co-
precipitated with either caspase-1 WT or caspase-1 C362, confirming
the interaction between Prdx4 and caspase-1 (Fig 4F). However,
Prdx4 co-precipitation was drastically reduced with the caspase-1
C397S or the C362S plus C397S mutants, underscoring the necessity
of caspase-1 C397 for the thiol-dependent interaction with Prdx4. In
order to reciprocally map the cysteine residues of Prdx4, we used
catalytic (C124, C245) and conformational (C51) Cys-to-Ala mutants
of Prdx4 that lack the ability to form functional decamers or multi-
mers as previously described (Tavender et al, 2008, 2010). Notably,
unlike WT Prdx4, all mutants tested failed to decrease the caspase-
1-induced IL-b secretion (Fig 4G) and showed loss of caspase-1
interaction (Fig 4H). Since the proper structure and function of the
high-molecular-weight form of Prdx4 is compromised in all mutants
tested (Tavender et al, 2008, 2010), we conclude that rather than a
particular cysteine of Prdx4, the high-molecular-weight conforma-
tion of Prdx4 is required for the interaction with the redox-sensitive
C397 of caspase-1 to block its function.
Prdx4 is secreted upon activation of the NLRP3 inflammasome
and co-localizes with caspase-1 in MVBs
In a next step, we explored whether and where endogenous Prdx4
and caspase-1 co-localize in cells under physiological conditions,
which is a prerequisite for their functional interaction. Several
compartments have been shown to be involved in inflammasome/
caspase-1-mediated IL-1b maturation and secretion, which may dif-
fer between cell types and activation states. In monocytes and
macrophages, evidence points to primary processing of pro-IL-1b in
the cytosol, while the lysosomal secretory pathway seems less
important (Singer et al, 1995; Brough & Rothwell, 2007). Prdx4 is
described to be mainly localized within the ER (Tavender et al,
2008; Zito et al, 2010; Kakihana et al, 2013) or can be secreted via
classical exocytosis (Matsumoto et al, 1999; Okado-Matsumoto
et al, 2000). Several systematic analyses of subcellular protein
localization (Itzhak et al, 2016; Thul et al, 2017), however, have
suggested that a pool of Prdx4 might be present in the cytosol, too.
We used cellular fractionation methods to address the question
where Prdx4 is localized under baseline conditions and whether
activation of the inflammasome has an influence on the cellular
compartmentalization of Prdx4. To this end, we stimulated BMDMs
with LPS or LPS+ATP and monitored levels of Prdx4 in the cytosol,
the insoluble fraction containing all membranous compartments
(including ER and Golgi) by Western blot [using a modified version
of the protocol by Song et al (2006)]. We show that (i) Prdx4 can
be found, as expected, in membranous compartments as well as in
the cytosolic fraction, where also caspase-1 and Gapdh are present.
(ii) Upon LPS and LPS+ATP stimulation, levels of Prdx4 increased
in both compartments (Fig 5A). LPS stimulation of BMDMs in vitro
led to a significant release of Prdx4 into the supernatant, which was
further increased by adding ATP (Fig 5B). LPS injection in mice
in vivo resulted in significantly elevated Prdx4 levels between 3 h
and 24 h post-LPS challenge (Fig 5C). Since high serum levels of
Prdx4 have been associated with disease severity in human sepsis
patients (Schulte et al, 2011), we sought to investigate the link
between Prdx4 secretion and inflammasome activation in more
detail. Thus, we next used YVAD to block caspase-1 activity and to
monitor Prdx4 release. We found that YVAD significantly reduced
levels of extracellular Prdx4 after LPS/ATP stimulation (Fig 5D),
indicating that Prdx4 secretion follows caspase-1 activation. In
◀ Figure 2. Role of IL-1 receptor blockade and myeloid-specific ablation of Prdx4 in the endotoxin-shock model.A Percent body weight of male Prdx4 WT and KO mice over the 48 h course of LPS (4.5 mg/kg BW) injection (i.p.) and treatment with IL-1 receptor antagonist (IL-1RA)
Anakinra (200 lg/mouse) or control. Arrows indicate time point of Anakinra injection. Each circle represents a mean of n = 5 mice; vertical lines indicate SEM.
***P < 0.001 (two-way-ANOVA, Bonferroni post-test).
B Serum concentration of Cxcl1, TNF-a, and IL-1b in Prdx4 WT and KO mice injected with LPS, LPS, and IL-1RA or control. Each dot represents an individual mouse.
Horizontal lines indicate mean. *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant (two-tailed t-test).
C Percent body weight of male Prdx4-flox and Prdx4-DLysMCre mice over the 48 h course of 4.5 mg/kg BW LPS (i.p.). Each circle represents a mean of n = 7 mice;
vertical lines indicate SEM. *P < 0.05; ***P < 0.001 (two-way-ANOVA, Bonferroni post-test).
D Serum concentration of Cxcl1, TNF-a, and IL-1b in Prdx4-flox and Prdx4-DLysMCre mice injected with LPS. Each dot represents an individual mouse. Horizontal lines
indicate mean. *P < 0.05; ***P < 0.001; n.s. not significant (two-tailed t-test). Data are representative of two independent experiments.
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order to evaluate the mode of Prdx4 release upon inflammasome
activation in more detail (Fig 5E), we next tested whether Prdx4 is
passively lost in response to pyroptotic membrane rupture. We
found that pretreatment with the cytoprotective agent glycine had
no effect on Prdx4 release (Fig 5F). In contrast, both blockage of
the pyroptotic pore-forming protein gasdermin D (GSDMD) by its
direct chemical inhibitor necrosulfonamide (NSA) (Rathkey et al,
2018) and inhibition of extracellular vesicle shedding by GW4869
(Kosaka et al, 2010; Mittelbrunn et al, 2011) significantly lowered
Prdx4 secretion. Together, these data suggest that Prdx4 is not
passively lost in response to inflammasome activation and its
release involves GSDMD-dependent mechanisms and also the
formation of extracellular vesicles. Of note, GW4869, which inhibits
the ceramide-mediated inward budding of multivesicular bodies
(MVBs) and release of mature extracellular vesicles from MVBs
(Trajkovic et al, 2008), also significantly diminished Prdx4 and
caspase-1 release into the medium. Although these experiments do
not provide definitive evidence for cytosolic Prdx4, we reasoned
that cytosolic Prdx4 together with cytosolic caspase-1 might be
sorted into MVBs and released via EVs from the cell. To further
confirm the presence of Prdx4 and caspase-1 in MVBs, we next
performed density gradient ultracentrifugation of LPS and ATP-
treated BMDMs to fractionate membranous compartments, includ-
ing MVBs. We found that Prdx4 was enriched in fraction I-III. More-
over, fraction I and II were exclusively positive for CD63, a reported
marker for MVBs (Kobayashi et al, 2000) (Fig 5G), suggesting that
Prdx4 is present in MVBs. The ER/Golgi protein Gosr1 was enriched
in fractions III and VI, whereas mitofilin, a marker for mitochon-
dria, was enriched in fractions V and VI. Fractions I-III, and to a
lesser extent fraction IV, were positive for the secretory protein
beta-2 microglobulin. When we investigated the fractionation of
caspase-1 and other inflammasome components, we found that Asc
was highly abundant in fraction I and II, pro-caspase-1 was
enriched in fraction II and III and as well as in fraction V and VI
and that pro-IL-1b was present in all fractions. Together, the data
show the complexity of the compartmentalization of pro-IL1b,
caspase-1, Prdx4, and the inflammasome apparatus. The results
suggest that Prdx4 and caspase-1 along with Asc and pro-IL-1b are
co-present in MVBs and led to the hypothesis that inflammasome
activation may trigger the shedding of MVB-derived extracellular
vesicles.
ATP-induced NLRP3 inflammasome activation leads to secretion
of distinct EVs from BMDMs
The data described above indicate that a proportion of the
inflammasome and Prdx4 are co-secreted upon inflammasome acti-
vation from macrophages, most likely originating from MVBs. To
examine whether vesicle shedding occurs in response to caspase-1
activation, we isolated and purified extracellular vesicles from the
supernatant of BMDMs that were untreated or LPS-primed in the
presence or absence of either ATP, nigericin, poly(dA:dT), or
flagellin to induce caspase-1-dependent inflammasome activation.
Subsequently, we applied several methods to comprehensively char-
acterize the EV isolates (Fig 6A). Our analyses demonstrated a
significant increase in protein concentration upon stimulation with
all inflammasome activators (Fig 6B), whereas the number of EVs
was exclusively enhanced after ATP- and nigericin stimulation
(Fig 6C). Interestingly, TEM data revealed the presence of EVs with
an average diameter of approximately 50 nm in all isolates except in
EVs derived from LPS+ATP-stimulated BMDMs, which exhibited an
average diameter of approximately 110 nm (Fig 6D and E). To vali-
date this finding, we independently determined the size distribution
profile by performing dynamic light scattering (DLS) measurements.
We obtained similar results using DLS particle analysis, confirming
that the average size of particles isolated from LPS+ATP-stimulated
BMDMs was higher compared to particles derived from unstimu-
lated BMDMs (Fig EV3A and B), thus demonstrating a shift in EV
size in response to ATP-induced NLRP3 inflammasome activation.
Moreover, we found that NLRP3 inflammasome activation led to
significantly increased levels of Prdx4, caspase-1, and IL-1b in EV
lysates compared to EVs from unstimulated or LPS-primed BMDMs
(Fig 6F and G). IL-1b, however, was also found to be significantly
increased in EV lysates from poly(dA:dT)- or flagellin-treated
BMDMs. Analysis of EV protein lysates from LPS and ATP-stimu-
lated BMDMs confirmed the presence of inflammasome compo-
nents, Prdx4, as well as positive and negative markers for EVs
(Fig EV3C). In order to investigate whether Prdx4 and caspase-1 are
◀ Figure 3. Prdx4-deficient macrophages display elevated cytokine responses and inflammasome activation.A Concentration of Cxcl1, TNF-a, and IL-1b in the supernatants of Prdx4 WT and KO BMDMs in response to a time course of LPS stimulation (100 ng/ml LPS, time
points indicated).
B IL-1b release of Prdx4 WT and KO BMDMs, untreated, or primed for 6 h with LPS (100 ng/ml) and then pulsed for indicated time points with ATP (5 mM).
C Western blot analysis of IL-1b in cell lysates and supernatants of Prdx4 WT and KO BMDMs, primed with LPS (100 ng/ml), and pulsed with ATP (5 mM) for 4 h or left
untreated. Dashed line indicates vertical slice.
D Immunofluorescence microscopy of ASC speck formation in Prdx4 WT and KO BMDMs in response to nigericin (10 lg/ml) stimulation for 45 min of LPS-primed cells.
Cells were stained with an antibody to ASC, and nuclei were counterstained using DAPI. Scale bar indicates 20 lm. ASC speck-positive cells were counted and
expressed as percentage of total cells. Bars represent a mean of n = 4 mice; vertical lines indicate SD. n.s. not significant (two-tailed t-test).
E Western blot analysis of caspase-1 cleavage in the supernatant of Prdx4 WT and KO BMDMs in response to nigericin (10 lg/ml) stimulation for 1 h after priming
with LPS (100 ng/ml), LPS priming alone or without stimulation. Whole-cell lysates were analyzed for pro-caspase-1 and Gapdh levels.
F IL-1b release in Prdx4 WT and KO BMDMs, untreated, or primed for 6 h with LPS (100 ng/ml) and then pulsed for 3 h with ATP (5 mM) or nigericin (10 lg/ml) or
transfected for 3 h with poly(dA:dT) or flagellin (1 lg/ml each) or treated with transfection agent only.
G Quantification of cell death by LDH release in Prdx4 WT and KO BMDMs, untreated, or primed for 6 h with LPS (100 ng/ml) and then pulsed for 3 h with ATP (5 mM)
or nigericin (10 lg/ml) or transfected for 3 h with poly(dA:dT) or flagellin (1 lg/ml each) or treated with transfection agent only.
Data information: (A, B) Each dot represents a mean of n = 3 mice; vertical lines indicate SD. **P < 0.01; ***P < 0.001 (two-way-ANOVA, Bonferroni post-test). (F, G) Bars
represent a mean of n = 3 mice; vertical lines indicate SD. *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant (two-tailed t-test). All data are representative of two
independent experiments.
Source data are available online for this figure.
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co-localized within the same vesicle, we used confocal microscopy
as previously described for EVs (Athman et al, 2015). We observed
a speckled co-localization of Prdx4 and caspase-1 on microscopy
slides, which were coated with isolated EVs derived from LPS+ATP-
stimulated BMDMs. Counterstain with a lipophilic dye suggested
that the co-localization is confined to lipid-containing structures,
which most likely represent the membranes of EVs (Fig EV4).
Collectively, these data indicate that distinct EV populations are
released in response to NLRP3 inflammasome activation, containing
constituents of the inflammasome as well as Prdx4.
Prdx4 controls caspase-1 cleavage and IL-1b maturation in
extracellular vesicles
The observation, that highest levels of Prdx4 were found in EVs
from LPS+ATP-treated cells and that Prdx4 and caspase-1 were co-
localized in the same EV particle, prompted us to investigate the
consequences of Prdx4 deletion for EV function. We therefore
isolated EVs from the supernatant of either untreated or LPS+ATP-
stimulated BMDMs from Prdx4 WT and KO as well as from Asc-defi-
cient mice. Upon LPS and ATP treatment, we detected Prdx4,
NLRP3, Asc, pro-caspase-1, and pro-IL-1b in CD63+ EVs (Fig 7A).
Using immunoprecipitation against caspase-1, we found increased
levels of cleaved caspase-1 p10 in EVs derived from Prdx4 KO
BMDMs compared to the WT. Together, this demonstrates that also
within EVs, caspase-1 activation is limited by Prdx4, resulting in
reduced caspase-1 cleavage in the presence of Prdx4. Because we
were unable to detect mature IL-1b in EVs by immunoblotting, we
asked whether we can determine IL-1b levels by detection of IL-1b-
mediated signaling. Given that the presence or absence of Prdx4
within EVs determines the intensity of caspase-1 cleavage and thus
levels of IL-1b, we reasoned that Prdx4 influences the ability of EVs
to induce IL-1b-immune responses in recipient cells. In order to test
our hypothesis, we followed a three-tiered approach (Fig 7B). First,
we used HEK-blue IL-1R reporter cells and stimulated them with
EVs isolated from Prdx4 WT or Prdx4 KO BMDMs. Induction of
secreted alkaline phosphatase (SEAP) activity was determined as a
measure for IL-1R activation. Second, caspase-1-deficient BMDMs
were used as recipient cells to exclude IL-1R activation from endoge-
nously derived IL-1b. Third, C57Bl/6N mice were injected with EVs
from Prdx4 WT and KO BMDMs using EV protein content as a
measure to control for the relative dose of administered EVs. Serum
Cxcl1 levels were determined 3 h post-injection. Following our first
approach, EVs from LPS and ATP-stimulated BMDMs induced a
significant increase in SEAP activity compared to EVs from either
unstimulated or LPS-treated BMDMs (Appendix Fig S6). Further-
more, in comparison with EVs from LPS and ATP-stimulated WT
donors, EVs derived from Prdx4 KO BMDMs led to significantly
higher SEAP activity. In caspase-1-deficient cells, we found that EVs
derived from LPS- as well as from LPS and ATP-stimulated BMDMs
induced Cxcl1 secretion compared to EVs from unstimulated cells
(Fig 7C). Again, EVs from Prdx4-deficient BMDMs induced a signifi-
cantly higher Cxcl1 response compared to EVs from WT donors.
Compared to this finding, inhibition of IL-1R by Anakinra signifi-
cantly reduced Cxcl1 levels, confirming the involvement of IL-1R
activation. We finally injected EVs from Prdx4 WT or KO mice as
well as from ASC KO mice in C57Bl/6N recipient mice. Analysis of
serum cytokine levels showed that Prdx4-deficient EVs induced a
higher Cxcl1 response compared to EVs from Prdx4 WT or ASC KO
mice (Fig 7D). Together, we found that (i) EVs, derived from
inflammasome-activated cells, are able to actively release IL-1b and
(ii) the presence of Prdx4 in EVs lowers the potency of IL-1b-
mediated pro-inflammatory responses in recipient cells or mice.
Discussion
Cellular release of IL-1b is a tightly regulated process and critical to
maintain immune homeostasis. Aberrantly high IL-1b levels have
been implicated in several inflammatory diseases, including
rheumatoid arthritis, osteoarthritis, gout, hereditary periodic fever,
and type II diabetes (Dinarello, 2009). Inflammasomes are multipro-
tein complexes that—after their regulated assembly in response to
danger signals—orchestrate caspase-1 activation and cleavage of
pro-IL-1b into its active form. Mechanisms that are required to
prime and activate inflammasomes are well described (reviewed in
◀ Figure 4. Prdx4 interacts with C397 of caspase-1 to block its function.A Western blot analysis of rPRDX4, rCASP-1, and co-incubated rPRDX4 and rCASP-1 after non-reducing SDS–PAGE. Black arrows at 250 kDa indicate the corresponding
molecular weights of rCASP-1 and rPRDX4 oligomers and decrease of the Prdx4 band intensity upon co-incubation with rCASP-1. Black arrow at approx. 50 kDa
indicates the appearance of an additional rPRDX4 band which corresponds to the molecular weight of a Prdx4 dimer.
B Western blot analysis of rPRDX4 (=P) and rCASP-1 (=C) after alkylation (=A) and non-reducing SDS–PAGE. Black arrows indicate the termination of the integration of
rCASP-1 into the rPRDX4 decamer/HMWC upon alkylation.
C Rate of caspase-1 activity in the presence of non-reduced decameric rPrdx4, reduced dimeric and monomeric rPRDX4, YVAD, or control.
D Fold change in IL-1b concentration in supernatants of HEK293 cells transfected with plasmids for NLRP3, ASC, IL-1b, and caspase-1 WT or Cys-to-Ser mutants C362S
or C397S and co-transfected with Prdx4 or control. Cells were stimulated with 2.5 mM ATP for 30 min before analysis.
E Western blot analysis of non-reducing SDS–PAGE of cell lysates from HEK293 cells transfected with caspase-1 WT, C362S, C397S, or C362S plus C397S mutants and co-
transfected with Prdx4-GFP or GFP as control.
F Western blot analysis of co-immunoprecipitation using HA-magnetic beads from cell lysates of HEK293 cells transfected with HA-tagged caspase-1 WT, C362S, C397S,
or C362S plus C397S mutants and co-transfected with Prdx4-GFP or GFP as control.
G IL-1b concentration in supernatants of HEK293 cells transfected with plasmids for NLRP3, ASC, IL-1b, and caspase-1 and co-transfected with Prdx4 WT or Cys-to-Ala
mutants C51A, C124A, C245A, or DM C124A/C245A or control. Cells were stimulated with 2.5 mM ATP for 30 min before analysis.
H Western blot analysis of co-immunoprecipitation using HA-magnetic beads from cell lysates of HEK293 cells transfected with HA-tagged caspase-1 WT or control and
co-transfected with Prdx4 WT or Cys-to-Ala mutants C51A, C124A, C245A, or DM C124A/C245A.
Data information: Data are representative of two (B, E, F) or three (A, C, D, G, H) independent experiments. Each bar represents a mean of triplicate wells; error bars
indicate SD. *P < 0.05; **P < 0.01; n.s. not significant (two-tailed t-test).
Source data are available online for this figure.
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He et al, 2016), yet little is known about endogenous factors that
negatively regulate caspase-1 activity and thus may limit the pro-
inflammatory cascade (Poudel & Gurung, 2018).
Our study unveils Prdx4 as a critical modulator of caspase-1
function. We show that mice lacking Prdx4 are highly sensitive to
endotoxic shock. Prdx4 KO BMDMs release increased amounts of
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IL-1b upon inflammasome activation. The in vivo phenotype could
be fully abolished by IL-1RA treatment and was phenocopied by a
conditional deletion of Prdx4 in the myeloid compartment.
Two salient observations emerge from the experiments
presented here: First, we show that the 2-Cys oxidoreductase Prdx4
directly regulates caspase-1 function in a redox-sensitive manner.
Several findings had already put peroxiredoxins in the context of
inflammatory signaling (Li et al, 2007; Yang et al, 2007; Lee et al,
2017). Members of the Prdx family were shown to reduce intracel-
lular ROS levels and to modulate cell death induced by pro-inflam-
matory stimuli (Rao et al, 2017). Whereas our initial assumption
was that the antioxidant properties of Prdx4 would affect ROS-
dependent inflammasome priming (Zhou et al, 2011), our data
showed no differences in transcriptional regulation of inflamma-
some components, or ASC speck formation between Prdx4 KO and
WT mice. Instead, we present experimental evidence that caspase-1
functionally interacts with Prdx4 via a redox-sensitive mechanism.
Regulation of the proteolytic activity of caspase-1 via an altered
cellular redox potential has been described previously. Its function
is impaired by reversible oxidation via intracellular superoxide
(Meissner et al, 2008), which can be abrogated by hypoxic condi-
tions or addition of exogenous DTT generation (Tassi et al, 2009).
Two cysteines in caspase-1 (Cys362 and Cys397) have been
proposed as redox-sensitive residues and are regulated by
glutathionylation (Meissner et al, 2008). Our data show that the
presence of high-molecular-weight oligomers of Prdx4 leads to inhi-
bition of caspase-1 activity under non-reducing conditions. In such
a milieu, Prdx4 has been shown to form stable oligomers, with a
preponderance of decamers consisting of five disulfide-linked Prdx4
dimers (Tavender et al, 2008; Cao et al, 2011). We show that
recombinant caspase-1 (p10 and p20 subunit) co-migrates at the
expected molecular weight of the recombinant Prdx4 decamer in a
non-reducing gel. Alkylation of either partner leads to an absence of
caspase-1 in the high-molecular-weight fraction. The data suggest
that caspase-1 is first integrated into the high-molecular-weight
complex of Prdx4 in a disulfide-dependent manner, forming a
redox-active complex with Prdx4, which finally leads to the inacti-
vation of caspase-1. Consistently, we find in a mutational analysis
of cysteines in caspase-1 that replacement of the cysteine at position
397 by a serine leads to an overall increase of caspase-1 activity.
Importantly, this effect is associated with a complete loss of the
blocking activity of Prdx4, a strong reduction of the mutated
caspase-1 in the high-molecular-weight fraction and ultimately loss
of physical interaction between caspase-1 and Prdx4, indicating the
necessity of the cysteine residue for the observed functional interac-
tion. Vice versa, Cys-to-Ala mutants of Prdx4, that lack the ability
◀ Figure 5. Prdx4 is secreted upon activation of the NLRP3 inflammasome and co-localizes with caspase-1 in MVBs.A Western blot analysis of Prdx4, pro-caspase-1, Gapdh, and E-Cadherin from the cytosolic and insoluble cell fraction of LPS and/or ATP-stimulated BMDMs or
untreated controls.
B Prdx4 concentration in supernatants of Prdx4 WT or KO BMDMs, primed for 6 h with LPS, and pulsed for indicated time points with 5 mM ATP. Each circle represents
a mean of n = 3 mice; vertical lines indicate SD. **P < 0.01; n.s. not significant (two-tailed t-test).
C Concentration of Prdx4 in the serum of WT mice, injected with LPS (4.5 mg/kg BW) for the time points indicated. Each dot represents an individual mouse. Horizontal
lines indicate mean. *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant (two-tailed t-test).
D Concentration of Prdx4 in supernatants of Prdx4 WT and KO BMDMs. Cells were primed with LPS (100 ng/ml) for 6 h, followed by pretreatment with 20 lM YVAD or
DMSO as control for 30 min and stimulated with 5 mM ATP for 4 h or no further stimulation. Each bar represents a mean of n = 3 mice; vertical lines indicate SD.
**P < 0.01; n.s. not significant (two-tailed t-test).
E Schematic illustration of selected mechanisms that were targeted by either glycine, necrosulfonamide (NSA), or GW4869 to study LPS+ATP-induced Prdx4 secretion.
F Relative levels of Prdx4 secretion in response to LPS+ATP stimulation and pretreatment with either glycine, NSA, or GW4869 and relative levels of caspase-1 secretion
in response to LPS+ATP stimulation and pretreatment with in response to LPS+ATP stimulation and pretreatment with GW4869. Each bar represents a mean of n = 3
biological with two technical replicates; vertical lines indicate SD. *P < 0.05; **P < 0.01; n.s. not significant (two-tailed t-test).
G Western blot analysis of subcellular organelle fractions. OptiPrep density gradient ultracentrifugation was used to fractionate subcellular organelles from Prdx4 WT
BMDMs that were primed with LPS (100 ng/ml) for 12 h and stimulated with 5 mM ATP for 4 h.
Data information: Data are representative of two (A, B, D, E) or three (G) independent experiments.
Source data are available online for this figure.
▸Figure 6. ATP-induced NLRP3 inflammasome activation leads to secretion of distinct EVs from BMDMs.A Schematic illustration of workflow for EV isolation and characterization (panels B–G) from BMDMs that were left untreated or LPS-primed in the presence or absence
of either ATP, nigericin, poly(dA:dT), or flagellin.
B BCA analysis of EV protein concentration in EVs isolates. Each bar represents a mean of n = 3 technical replicates; vertical lines indicate SD. *P < 0.05; **P < 0.01;
***P < 0.001; n.s. not significant (two-tailed t-test).
C Exocet quantification assay of EVs particle numbers. Each bar represents a mean of n = 3 technical replicates; vertical lines indicate SD. *P < 0.05; ***P < 0.001; n.s.
not significant (two-tailed t-test).
D Transmission electron microscopy (TEM) of EV isolates. Three representative pictures are displayed. Scale bar indicates 200 nm.
E Analysis of size distribution of EVs. Each dot indicates the diameter in nm of an individual vesicle. SD. ***P < 0.001; n.s. not significant (one-way ANOVA, followed by
a Tukey multiple comparison test).
F Prdx4 concentration in EV lysates. Each bar represents a mean of n = 2 technical replicates; vertical lines indicate SD. **P < 0.01; ***P < 0.001; n.s. not significant
(two-tailed t-test).
G Caspase-1 and IL-1b concentration in EV lysates. Each bar represents a mean of n = 2 technical replicates; vertical lines indicate SD. **P < 0.01; ***P < 0.001; n.s. not
significant (two-tailed t-test).
Data information: Data are representative of two (D, E) or three (B, C, F, G) independent experiments.
Source data are available online for this figure.
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to form functional high-molecular-weight oligomers (Tavender
et al, 2008, 2010), showed a loss of the caspase-1 interaction and
failed to inhibit caspase-1-induced IL-1b secretion. Altogether, our
findings highlight the critical role of high-molecular-weight
oligomers of Prdx4 for a novel redox-dependent regulatory mecha-
nism of caspase-1 activity.
The second important observation is related to the extracellular
compartment of the functional interaction of Prdx4 with caspase-1.
A B
C D
Figure 7. Prdx4 controls caspase-1 cleavage and IL-1b maturation in extracellular vesicles.
A Western blot analysis of Prdx4, NLRP3, ASC, caspase-1, IL-1b, and CD63 from EV lysates (upper panel) or caspase-1 after immunoprecipitation against caspase-1
(lower panel).
B EVs isolated from donor BMDMs were transferred to recipient cells or mice followed by subsequent readout of inflammatory response markers.
C Cxcl1 concentration in supernatants of caspase-1-deficient BMDMs stimulated with EVs from LPS, LPS, and ATP or control-treated Prdx4 WT or KO BMDMs, as well as
caspase-1-deficient BMDMs pre-treated with Anakinra and stimulated with EVs from LPS and ATP-treated Prdx4 WT or KO BMDMs. Each bar represents a mean of
n = 3 biological with two technical replicates; vertical lines indicate SD. *P < 0.05; **P < 0.01; n.s. not significant (two-tailed t-test).
D Serum Cxcl1 in C57Bl6/N mice injected with either PBS or EVs from LPS and ATP or control-treated Prdx4 WT or KO or ASC KO BMDMs. Each dot represents an
individual mouse. Horizontal lines indicate mean.
Data information: Data are representative of two (C, D) or three (A) independent experiments.
Source data are available online for this figure.
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In line with other studies, we show that Prdx4 is upregulated and
secreted upon induction of inflammation (Matsumoto et al, 1999;
Okado-Matsumoto et al, 2000; Wong et al, 2000). Strikingly, we
find that extracellular Prdx4 is located in extracellular vesicles,
where it co-localizes with caspase-1. An extracellular role of the
inflammasome and its components has already been suggested
(Baroja-Mazo et al, 2014; Franklin et al, 2014; Mitra et al, 2015). In
particular, ASC specks have been shown to accumulate in the extra-
cellular space, where they promoted IL-1b maturation (Franklin
et al, 2014). Moreover, IL-1b, caspase-1, and other inflammasome
components have been described to localize to exosomes (Qu et al,
2007) and it was suggested from a meta-analysis of proteomic and
protein interaction data that caspase-1 cleaves its substrates to prop-
agate inflammation to neighboring and remote cells in extracellular
vesicles (Wang et al, 2016). Yet, the exact role of their presence in
the compartment remained unclear. Our data critically expand and
underscore these observations by demonstrating that inflamma-
some-containing extracellular vesicles (EVs) induce an IL-1b-depen-
dent pro-inflammatory signal in recipient cells. The loss of Prdx4
boosted the potential of EVs to transmit the immune response
in vitro and in vivo, thereby defining a critical role for Prdx4 in the
regulation of inflammasome-mediated responses. These findings
unveil a novel long-range effect of inflammasomes via transport in
macrophage-derived EVs.
In conclusion, we propose that the transmission of inflammasome
components and mature IL-1b by EVs constitutes a mechanism for
the propagation of inflammation in remote cells and organs. At the
same time, the net inflammatory potential of EVs is influenced by
the presence of the redox-active constituent Prdx4 that negatively
regulate caspase-1 activity. A targeted modulation of the redox
balance would therefore open new avenues for anti-inflammatory
strategies. In particular in patients suffering from septicemia, high
Prdx4 serum concentrations were associated with increased disease
severity (Schulte et al, 2011). It is unclear in how far these elevated
Prdx4 levels reflect the physiological attempt to dampen excessive
inflammation or the pathological condition suppressing systemic
immune functions. We suggest, that the spatiotemporal control of
the redox environment within EVs plays a key role in the regulation
of inflammasome activity, where under hypoxic conditions—such as
in local infections or tumors—inflammasomes in EVs would be
biased to secrete IL-1b. Future studies are needed to translate these
findings to humans and carefully evaluate intervention strategies,
which could exploit this principle in inflammatory conditions.
Materials and Methods
Mice
Prdx4 constitutive and conditional knockout mice were generated
by a commercial supplier (GenOway) and were back-crossed onto
C57Bl/6N background for at least 10 generations. Exon 1 of Prdx4
was flanked by LoxP sites to enable its excision by Cre recombinase.
Deletion of exon 1 resulted in the deletion of the ATG initiation
codon and thus absence of transcription. To obtain constitutive
knockout mice, Prdx4 flox/flox mice were crossed to ubiquitous
Cre-deleter mice. Mice were housed under specific pathogen-free
(SPF) conditions in individual-ventilated cages (IVCs) in a 12-h
light–dark cycle and were provided with a standard rodent diet and
food and water ad libitum. Male mice, aged 8–12 weeks, were used
for in vivo experiments. Bone marrow-derived macrophages
(BMDMs) were generated from age-matched males or females from
8 to 20 weeks of age. Hemizygous Prdx4 KO and WT F1 littermates
were obtained by crossing heterozygous females to WT C57Bl/6N
males. For inflammasome-related studies, the following strains were
used: caspase-1-KO (Casp1tm2.1Flv) (Blazejewski et al, 2017) and
ASC KO (B6.129S2-ASCtm1Sesh) (Ozoren et al, 2006) mice. All experi-
ments were carried out according to the German Animal Protection
Law and in accordance with the guidelines for Animal Care of the
University of Kiel Votes No.: V242-2904/2019 (18-2/19), V242-
7224.121-33 (99-7/13) and (156-11/13).
Reagents and antibodies
Nigericin (trlrl-nig), poly(dA:dT) dsDNA (tlrl-patn), ultrapure
flagellin (tlrl-pstfla5), and ultrapure LPS (tlrl-peklps) were from
Invivogen. Deep-rough LPS (Kdo2-lipid A) from E. coli F515 or
KPM53 (Mamat et al, 2009) was prepared according to published
protocols (KPM53: Ranf et al, 2015); F515: Zahringer et al, 2001).
The triethylamine salt of the deep-rough LPS was formed
(Zahringer et al, 2001) prior to its use in any conducted experi-
ment. Fugene 6 was from Promega. ATP and DMSO were from
Sigma. Active recombinant human Prdx4 was from Abcam
(ab93947); active recombinant human caspase-1 was from Enzo
Life Sciences (ALX-201-056). Caspase-1 fluorometric assay kit was
from Enzo (ALX-850-212-KI01). Caspase-1 inhibitor Ac-YVAD-cmk
was from Invivogen (inh-yvad). IL-1R-antagonist Anakinra
(Kineret) was from Swedish Orphan Biovitrum. The following
antibodies were used: rabbit antibody to mouse Prdx4 (ab59542;
Abcam), mouse antibody to human Prdx4 (ab16943; Abcam),
rabbit antibody to mouse caspase-1 (sc-514; Santa Cruz Biotechnol-
ogy), goat antibody to mouse IL-1b (AF 401-NA; R&D Systems),
rabbit antibody to ASC (AG-25B-0067; AdipoGen), rabbit antibody
to CD63 (EXOAB-CD63A-1; SBI System Bioscience), mouse anti-
body to b-actin (A-5441; Sigma), mouse antibody to DDK
(TA50011-100; Origene), rabbit antibody to turboGFP (AB513;
evrogen). All HRP-conjugated secondary antibodies were obtained
from TH Geyer. Mouse cytokines were determined in culture
supernatants or serum with ELISA Kits from R&D Systems Cxcl1
(DY453), Life Technologies: IL-1b (CMC0813) and cloud clone:
Prdx4 (SEF754HU).
Cell culture, plasmids, and transfection
HEK cells were purchased from the German Collection of Microor-
ganisms and Cell Cultures (DSMZ) and maintained in RPMI medium
containing 10% (v/v) fetal calf serum (FCS) at 37°C with 5% CO2.
Transfections were performed at 24 h post-seeding using Fugene6
according to the manufacturer’s instructions (Roche). Myc-DDK and
GFP-tagged plasmids encoding the full length coding sequences of
human ASC/PYCARD, CASPASE-1, IL-1b, PRDX4, and empty
controls were purchased from Origene (pCMV6-Entry-PYCARD,
RC215592; pCMV6-Entry-CASP1, RC218364; pCMV6-Entry-IL1B,
RC202079; pCMV6-AC-GFP PRDX4, RG203330; pCMV6-Entry,
PS100001; pCMV6-AC-GFP; PS1000010). HA-tagged caspase-1 p10,
p20 WT, and p20 C285S mutant were described in Keller et al
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(2008). Further HA-tagged caspase-1 Cys-to-Ser mutants were
described in Meissner et al (2008).
LPS-induced sub-lethal endotoxic shock
Mice 8–12 weeks of age were injected intraperitoneally with a dose
of 4.5 mg E. coli F515 LPS per kg body weight or NaCl as control.
Mice were weighed and monitored for signs of endotoxemia every
6 h over the time course of the experiment. A drop of weight below
20% of initial body weight and/or signs of a severely impaired state
of health led to the exclusion from the experiment. For analysis of
serum cytokines, blood was obtained by cardiac puncture after keta-
mine/xylazine anesthesia. Cytokines were determined by ELISA.
Mice were killed by cervical dislocation, and spleens were removed
and weighed.
Isolation and generation of murine bone marrow-derived
macrophages (BMDMs)
Femur and tibia were removed, and bone marrow was isolated
under sterile conditions. BMDMs were cultivated for 7 days on 145-
mm-diameter Petri dishes in BMDM medium consisting of macro-
phage SFM medium and DMEM (Gibco) in a one-to-one ratio and
containing 10% FCS (Biochrom) and 1% penicillin/streptomycin
(Gibco) plus 1% Fungizone (Thermo), supplemented with 20 ng/ml
recombinant murine macrophage colony-stimulating factor (rm
M-CSF, Immunotools).
Inflammasome assays
BMDMs were plated in 96- to 6-well plates according to assay
requirements in BMDM medium consisting of macrophage SFM
medium and DMEM (Gibco) in a one-to-one ratio and containing
10% FCS (Biochrom) and 1% penicillin/streptomycin (Gibco) plus
1% Fungizone (Thermo), supplemented with 20 ng/ml recombi-
nant murine macrophage colony-stimulating factor (rm M-CSF,
Immunotools). FCS was omitted from the media when supernatants
were used for concentration and subsequent Western blotting. Cells
were primed with ultrapure LPS for 6 h and treated with inflamma-
some activators for 0.5–6 h. Fugene 6 was used to transfect poly
(dA:dT) or flagellin (1 lg/ml each). Transfection complexes were
incubated for 1 h at room temperature and added onto cells
followed by centrifugation of 4 min at 300 ×g. As a control, cells
were treated with transfection agent only. All stimulations were at
least performed in triplets, and cytokine production was monitored
by ELISA. For Western blot analysis, cells were lysed in 1% SDS-
containing lysis buffer in the presence of protease inhibitors or
supernatants were precipitated using chloroform/methanol extrac-
tion as described in Gross (2012) or concentrated using Amicon
ultra-0.5 or 2 ml centrifugal for protein purification (Merck). LDH
release into the cell culture supernatant was quantified using Pierce
LDH Cytotoxicity Assay (Thermo Scientific).
SDS–PAGE & MS
Lyophilized recombinant human active caspase-1 (Enzo Life
Sciences; ALX-201-056) was dissolved in HEPES buffer (20 mM, pH
7.2) to a concentration of 0.25 lg/ll (0.625 U/ll). Recombinant
human Prdx4 (Abcam; AB93947) was diluted with water to a
concentration of 0.5 lg/ll. Aliquots of 4 ll rCaspase-1 solution
were incubated with 1.1 lg of rPrdx4 protein. All samples were
diluted to a volume of 10 ll by adding water and then incubated at
37°C for 3 h.
Afterward, single protein samples, as well as mixed samples,
were separated by SDS–PAGE using a 4% polyacrylamide stacking
gel above a 10% resolving gel for separation or a 4–20% precast
gradient gel (Bio-Rad; Mini-PROTEAN TGX gel), respectively. SDS–
PAGE was performed according to the standard protocol, under
non-reducing conditions using a Mini-PROTEAN Tetra Cell as
described in the instructions of the manufacturer (Bio-Rad). Briefly,
the samples were mixed with 5 ll of Laemmli sample buffer with or
without DTT (5%) for reducing or non-reducing condition, respec-
tively. Samples including DTT were heated for 5 min at 60°C. Gels
used for Western blotting were loaded with 1:10 of the protein
concentration. Samples were loaded into the gel wells, along with a
molecular weight marker, and then separated by first applying a
constant voltage of 60 V for 15 min and then 100 V until the
running front reached the bottom of the gel. Gels were stained by
Coomassie and protein bands were excised for subsequent in-gel
digestion and LC-MS analysis. Alternatively, proteins were trans-
ferred onto membrane for Western blot. After adding 10 ll (0.5 lg)
of trypsin in 0.1 M TEAB, the samples were incubated for 16 h at
37°C. The digestion was stopped by adding 3 ll of FA, lyophilized
to dryness, and reconstituted in 15 ll of HPLC loading buffer (3%
ACN, 0.05% TFA in water).
LC-MS analysis
Digested peptide samples were analyzed by LC-MS. A Dionex U3000
HPLC system was coupled to a Q Exactive Plus mass spectrometer or
the Orbitrap Velos mass spectrometer (Thermo Fisher Scientific).
The digested samples were analyzed in duplicate. Samples were
injected on a C18 PepMap 100 l-precolumn (column dimensions:
300 lm i.d. × 5 mm; Thermo Scientific) with a flow rate of
30 ll/min, trapped and desalted for 2 min, and then separated on an
Acclaim PepMap RSLC column (column dimension: 75 lm
i.d. × 50 cm; Thermo Scientific) over a gradient of eluent A (0.05%
aqueous FA) and eluent B (80% ACN, 0.04% FA) with a flow rate of
0.3 ll/min. Peptides were eluted using a gradient from 5% eluent B
to 20% eluent B in 100 min, then to 40% B in 80 min, followed by
an increased to 90% eluent B in 8 min. After isocratic elution at 90%
eluent B for 10 min, the column was equilibrated for 15 min with
5% eluent B. After each sample LC run, the column was washed
using a blank run, injecting 5 ll of loading buffer. The LC-system
was directly coupled to the Q Exactive Plus mass spectrometer. Full
MS scans were acquired from 4 min to 72 min in positive ion mode
with a resolution of 70,000, an AGC target of 1e5, maximum
injection time of 50 ms with a scan range for 350 to 1,400 m/z.
Data-dependent MS/MS spectra of the ten most intense precursor
ions were acquired with a resolution of 7,500; scan parameters were
set to an isolation window of 1.2 m/z, a normalized collision energy
of 27, the AGC target of 1e5 and a maximum injection time of
100 ms. Precursors with a charge states < 2 and > 6 as well as
isotopes were excluded and precursors were excluded from subse-
quent isolation for 10 s. MS raw files were searched against a data-
base containing E. coli (the expression system), the two recombinant
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human proteins and common contaminants using Sequest search
algorithm and the Proteome discoverer software (Thermo Fisher
Scientific). Peptide spectrum matches and protein identifications
were restricted to a false discovery rate below 1%.
Alkylation assay
For alkylation of Prdx4 or caspase-1 cysteines, disulfide bonds were
reduced with 10 mM DTT at 56°C for 30 min. Free cysteine residues
were then alkylated with 20 mM iodoacetamide for 20 min at room
temperature in the dark. The reaction was quenched using 1%
formic acid.
Immunoprecipitation, co-immunoprecipitation, and
Western blotting
For immunoprecipitation of WT and mutant caspase-1 and their co-
incubation with rPrdx4, HEK293 cells were transfected as indicated
with plasmids for HA-tagged caspase-1 p10 plus p20 WT and p10
plus p20 C285S active-site mutant or empty HA as control. For co-
immunoprecipitation of WT and Cys-to-Ser mutants C362 or C397 of
caspase-1 with Prdx4, HEK293 cells were transfected as indicated
with plasmids for HA-tagged caspase-1 WT, caspase-1 C362S,
caspase-1 C397S, caspase-1 C362S plus C397S, or an empty HA
control and co-transfected with either Prdx4-GFP or empty GFP as
control. At 24 h after transfection, cells were lysed in RIPA Buffer
(50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.25% Na-deoxycholate,
1% NP-40) in the presence of PMSF inhibitor and proteins were
captured by Anti-HA Magnetic Beads (Thermo Scientific) following
the manufacturer’s instructions. Eluates were incubated for 1 h with
recombinant Prdx4 or left untreated or precipitates were washed,
eluted, and separated by SDS–PAGE. For immunoprecipitation of
endogenous caspase-1 from EVs, EVs were lysed in RIPA buffer
(50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.25% Na-deoxycholate,
1% NP-40) in the presence of PMSF inhibitor and caspase-1 was
captured using caspase-1 antibodies and Dynabeads (Thermo Scien-
tific) according to the manufacturers’ protocol. For non-reducing
SDS–PAGE, DTT was omitted from loading buffer and samples were
not boiled. After transfer onto polyvinylidene difluoride membranes
(Millipore), membranes were blocked with 5% non-fat dried milk
and probed with primary antibodies as indicated, washed, and incu-
bated with peroxidase-conjugated secondary antibodies. Proteins
were visualized using chemiluminescent substrates (ECL, Amersham
Biosciences) and exposure to X-ray films (Hyperfilm, Amersham).
ASC speck visualization
1 × 105 BMDMs were seeded on 8-wells Nunc Lab-Tek II Chamber
Slides (Thermo Scientific) and allowed to sit for 1 day. Cells were
then pre-treated with 100 ng/ml ultrapure LPS for 6 h or left
untreated, followed by stimulation with 10 lg/ml nigericin for
45 min or no further stimulation. Cells were washed, fixed in 4%
paraformaldehyde-PBS, blocked for 1 h in 1% BSA-PBS and incu-
bated with primary (1:300 of anti-ASC, AG-25B-0067, AdipoGen)
and secondary (1:500 of AF488 donkey anti-rabbit; A21206, Thermo
Scientific) antibodies for 1 h. DAPI was used for DNA counterstain-
ing. Images were acquired using a Zeiss AxioImager.Z1 apotome
fluorescence microscope and the AxioVision Imaging software
(Carl Zeiss MicroImaging Inc.). For each genotype, ASC specks were
counted and calculated as % of ASC speck+ cells.
Caspase-1 activity assay
Activity of recombinant human caspase-1 was determined in the
presence or absence of Prdx4 using the fluorogenic substrate YVAD-
AFC (ENZO). A final concentration of 1 U/ll of rCaspase-1 was
prepared in caspase-1 reaction buffer consisting of 50 mM Hepes,
pH 7.2, 50 mM sodium chloride, 0.1% Chaps, 10 mM EDTA, and
5% glycerol. Recombinant Prdx4 was added in a final concentration
of 10 ng/ll and was either reduced with 1 mM DTT or left
untreated. As control, YVAD (Invivogen)) was used at a concentra-
tion of 20 lM to block caspase-1 activity. Fluorescence was quanti-
fied using a fluorescence microtiter plate reader at 505 nm.
Isolation of extracellular vesicles
For isolation of extracellular vesicles, the Total Exosome Isolation
Reagent from cell culture media (Thermo Scientific) was used. After
differentiation, BMDMs were seeded in a density of 1 × 107 cells/
10 ml dish. FCS supplement in BMDM media was replaced by
exosome-depleted FCS (Thermo Scientific). In order to avoid carry-
over of LPS after the LPS priming step, BMDMs were rinsed twice
with pre-warmed PBS before stimulation with ATP. After ATP stim-
ulation, cell culture media was harvested and centrifuged at
2,000 ×g for 30 min at 4°C to remove cells and debris. The super-
natant was transferred into a new tube and mixed with the reagent
mixture well by vortexing. Samples were incubated overnight at
4°C. After incubation, samples were centrifuged at 10,000 ×g for 1 h
at 4°C. The supernatant was carefully discarded. Extracellular vesi-
cles were resuspended in PBS. To remove ATP and possible contam-
inants, Exosome Spin Columns (MW3000, Thermo Scientific) were
used according to the manufacturer’s protocol. The protein content
of the EVs was determined using BCA protein assay (Pierce), and
subsequent stimulations and injections were carried out using equal
amounts of EV protein.
Cell fractionation
BMDMs were rinsed twice with PBS, pelleted in 250 ll ice-cold RSB
buffer (10 mM Tris HCl, pH 7.4, 10 mM NaCl, 1.5 mM MgCl,
10 mM NaF) containing protease and phosphatase inhibitors, incu-
bated on ice for 5 min, and passed 15 times through a 26-gauge
needle. Lysates were centrifuged for 10 min at 1,000 ×g, and the
supernatants were subsequently centrifuged for 30 min at
20,000 ×g. The cytosolic fraction was derived from the supernatant
and the insoluble fraction was derived from re-suspension of the
pellet in 30 ll PBS. Protein concentrations were determined using a
protein assay (Bio-Rad) and equilibrated before loading.
Subcellular fractionation
For subcellular fractionation, a protocol described by Schmidt et al
(2009) was used. In brief, a total number of approximately 1 × 108
BMDMs were used. BMDMs were stimulated with LPS (KPM53) for
12 h and pulsed with 2.5 mM ATP for 4 h. BMDMs were washed
once with ice-cold PBS and resuspended in 2.5 ml extraction buffer
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including a protease inhibitor cocktail (Sigma). Gradient media and
buffers were purchased as a kit from Sigma. The cells were
disrupted in a dounce glass homogenizer with a small clearance
pestle using 25 strokes. For the initial enrichment of organelles, the
homogenates were separated by centrifugation at 1,000 ×g for
10 min to pellet nuclei and remaining intact cells. The post-nuclear
supernatant was sedimented at 20,000 ×g for 20 min. The resulting
pellet was adjusted to 19% (v/v) Optiprep (Sigma), loaded in the
middle of a non-ionic, low osmotic discontinuous density gradient
with 27, 22.5, 19, 16, 12, 8% Optiprep, and subjected to an ultra-
centrifugation at 150,000 ×g for 5 h. The osmolarity was adjusted to
290 mOsm with 2.3 M sucrose. The subcellular fractions were
collected from the top of the tube, washed, and concentrated with
HB buffer (250 mM sucrose, 10 mM Hepes pH 7.3 and 0.3 mM
EDTA) at 150,000 ×g for 20 min. All ultracentrifugation steps were
carried out at 4°C in Ultra-Clear centrifugation tubes in a swing-out
rotor (SW60Ti, Beckman Coulter). The protein content of the indi-
vidual fractions was determined using a BCA protein assay (Pierce).
Transmission electron microscopy (TEM) and dynamic light
scattering (DLS) spectroscopy of extracellular vesicles
TEM was performed as described before (Arnold et al, 2014). In
brief, 5 ll EV solution was added to a previously negatively glow
discharged carbon covered cooper grid (Science Service, Munich,
Germany). After removal of the solution with filter paper, the grid
was washed with half saturated uranyl acetate twice and then air-
dried. Images were taken on a JEM1400Plus (JEOL, Munich,
Germany) operating at 100 kV using a 4kx4k digital camera (F416,
TVIPS, Munich Germany) with a resolution of 4.58 A˚/pixel. Diame-
ter analysis was performed in EMMENU4 (TVIPS, Munich,
Germany) using the measure tool.
DLS was measured in a laser spectroscatter 201 (RiNA Gmbh,
Berlin, Germany) at 660 nm using a quartz cuvette. For each
sample, eight repetitive measurements (5 s at 20°C) were conducted
and the average is displayed.
Expression analysis
Total RNA was isolated using the RNeasy Mini kit (Qiagen). Reverse
transcription was achieved using the Maxima H Minus First Strand
cDNA Synthesis kit (Thermo Scientific). Quantitative real-time PCR
was performed using the TaqMan Gene Expression Master Mix
(Applied Biosystems) according to the manufacturer0s protocol and
analyzed by the 7900HT Fast Real-Time PCR System (Applied Biosys-
tems). Taqman assays were ordered from Applied Biosystems. Total
RNA (1 lg) was reverse-transcribed to cDNA according to the manu-
facturer’s instructions (MultiScribe Reverse Transcriptase, Applied
Biosystems). Reactions were carried out on the ABI PRISM Sequence
7700 Detection System (Applied Biosystems), and relative transcript
levels were determined using GAPDH as a housekeeper marker using
the standard curve method (Livak & Schmittgen, 2001).
Statistical analyses
GraphPad Prism 5 software was used for statistical analyses and
visualization. Data were analyzed for normal distribution using
Shapiro–Wilk normality test. Normally distributed data were
analyzed for significant group differences using a two-tailed
unpaired Student’s t-test. Nonparametric Mann–Whitney t-test (two-
tailed) was used for non-normally distributed data. For repeated
measures over time, two-way analysis of variance (ANOVA) and
Bonferroni post-test were performed. P < 0.05 were considered
statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
Expanded View for this article is available online.
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